Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 17:22:117-122.
doi: 10.1016/j.ijcha.2018.12.017. eCollection 2019 Mar.

Gender differences and management of stroke risk of nonvalvular atrial fibrillation in an upper middle-income country: Insights from the CARMEN-AF registry

J Antonio González-Hermosillo  1 , Manuel A Baños-González  2 , Milton E Guevara-Valdivia  3 , Jorge A Vázquez-Acosta  4 , Manuel Odín de Los Ríos Ibarra  5 , Kulio A Aguilar-Linares  6 , Carlos Cantú-Brito  7 , José L Leiva-Pons  8 , Gerardo Pozas-Garza  9 , Eddie A Favela-Pérez  10 , Manlio F Márquez  1 ; CARMEN-AF Committees and Investigators
Collaborators, Affiliations

Gender differences and management of stroke risk of nonvalvular atrial fibrillation in an upper middle-income country: Insights from the CARMEN-AF registry

J Antonio González-Hermosillo et al. Int J Cardiol Heart Vasc. .

Abstract

Background: Atrial Fibrillation (AF) is associated with an increased risk of stroke and systemic embolism. Several studies have suggested that female AF patients could have a greater risk for stroke. There is scarce information about clinical characteristics and use of antithrombotic therapies in Latin American patients with nonvalvular AF.

Objective: To describe the gender differences in clinical characteristics, thromboembolic risk, and antithrombotic therapy of patients with nonvalvular AF recruited in Mexico, an upper middle-income country, into the prospective national CARMEN-AF Registry.

Methods: A total of 1423 consecutive patients, with at least one thromboembolic risk factor were enrolled in CARMEN-AF Registry during a three-year period (2014-2017). They were categorized according to Gender.

Results: Overall, 48.6% were women, mean age 70 ± 12 years. Diabetes, smoking, alcoholism, non-ischemic cardiomyopathy, coronary artery disease, and obstructive sleep apnea were higher in men. Most women were found with paroxysmal AF (40.6%), and most men with permanent AF (44.0%). No gender differences were found in the use of vitamin K antagonists (VKA) (30.5% in women vs. 28.0% in men). No gender differences were found in the use of direct oral anticoagulants (DOAC) (33.8% women vs 35.4% men).

Conclusions: CARMEN-AF Registry demonstrates that in Mexico, regardless of gender, a large proportion of patients remain undertreated. No gender differences were found in the use of VKA or DOAC.

Keywords: AF, Atrial fibrillation; APD, Antiplatelet drugs; ATT, Antithrombotic therapy; Antithrombotic therapy; Atrial fibrillation; DOAC, Direct oral anticoagulants; Gender; Mexico; Stroke; Thromboembolic risk; VKA, Vitamin K antagonists.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Gender and stroke risk based on CHA2DS2-VASc. *P value was obtained comparing Gender groups using Chi-square test.
Fig. 2
Fig. 2
Gender and bleeding risk based on HAS-BLED. *P value was obtained comparing Gender groups using Chi-square test.
Fig. 3
Fig. 3
Gender and antithrombotic therapy according to CHA2DS2-VASc risk. *P value was obtained comparing Gender groups using Chi-square test.
See this image and copyright information in PMC

References

    1. Friberg L., Bergfeldt L. Atrial fibrillation prevalence revisited. J. Intern. Med. 2013 - PubMed
    1. Heeringa J., Van Der Kuip D.A.M., Hofman A., Kors J.A., Van Herpen G., Stricker B.H.C., Stijnen T., Lip G.Y.H., Witteman J.C.M. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur. Heart J. 2006 - PubMed
    1. Lloyd-Jones D.M., Wang T.J., Leip E.P., Larson M.G., Levy D., Vasan R.S., D'Agostino R.B., Massaro J.M., Beiser A., Wolf P.A., Benjamin E.J. Lifetime risk for development of atrial fibrillation: the Framingham heart study. Circulation. 2004 - PubMed
    1. Lip G.Y.H., Nieuwlaat R., Pisters R., Lane D.A., Crijns H.J.G.M. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest. 2010 - PubMed
    1. Mazurek M., Huisman M.V., Rothman K.J., Paquette M., Teutsch C., Diener H.C., Dubner S.J., Halperin J.L., Zint K., França L.R., Lu S., Lip G.Y.H. Gender differences in antithrombotic treatment for newly diagnosed atrial fibrillation: the GLORIA-AF registry program. Am. J. Med. 2018;131:945–955.e3. - PubMed